Regeneron Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Regeneron Pharmaceuticals is a leading American pharmaceutical company headquartered in New York City. Founded in 1988 by professor of medicine Leonard Schleifer and scientist George Yankupulos. Engaged in the development and production of drugs for various treatment methods.
Regeneron Pharmaceuticals stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Regeneron Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Regeneron Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Regeneron Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Regeneron Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Regeneron Pharmaceuticals assets
Regeneron Pharmaceuticals cash flows

Regeneron Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
REGN:USRegeneron Pharmaceuticals Inc.Common share-US75886F1075$967.2
Regeneron Pharmaceuticals news
02.11.2023
Regeneron Pharmaceuticals' GAAP net income for 9 months of 2023 was $2.794 billion, down 11% from $3.141 billion in the prior year. Revenue increased 10.5% to $9.683 billion from $8.759 billion a year earlier.
Source: {source} pictogram investor.regeneron.com
Pictogram next
03.08.2023
Regeneron Pharmaceuticals' GAAP net income for 6 months of 2023 was $1.786 billion, down 2.2% from $1.826 billion in the prior year. Revenue increased 8.6% to $6.32 billion from $5.822 billion a year earlier.
Source: {source} pictogram investor.regeneron.com
Pictogram next
04.05.2023
Regeneron Pharmaceuticals' GAAP net income for 3 months of 2023 was $817.8 million, down 16% from $973.5 million in the previous year. Revenue increased 6.6% to $3.162 billion from $2.965 billion a year earlier.
Source: {source} pictogram investor.regeneron.com
Pictogram next
03.02.2023
Regeneron Pharmaceuticals' GAAP net income for 2022 was $4.338 billion, down twofold from $8.075 billion in the previous year. Revenue fell 24.3% to $12.173 billion from $16.072 billion a year earlier.
Source: {source} pictogram investor.regeneron.com
Pictogram next
All Regeneron Pharmaceuticals news
General information
Company nameRegeneron Pharmaceuticals
Tags#biotechnology, #s&p500 index, #coronavirus, #vaccines
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 9148477000
Mailing address777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591
Websitewww.regeneron.com
Information disclosurewww.sec.gov